BRCA1 and ovarian carcinoma: SOLO2/ENGOT-Ov21 is a double-blind, randomized, placebo-controlled, multicenter, Phase III clinical trial that compared the efficacy of olaparib tablets as maintenance therapy in platinum-sensitive recurrent ovarian cancer patients with BRCA1/2 mutations.